Transforming CAR T Monitoring: The Power of the ExPeCT AntiCD19 (obe-cel) Assay

Transforming CAR T Monitoring: The Power of the ExPeCT AntiCD19 (obe-cel) Assay 

As CAR T-cell therapies continue to reshape treatment pathways for B-cell malignancies, clinicians and laboratories share a common challenge: understanding how engineered T-cells behave once they enter the patient. Expansion, peak response, persistence, and eventual contraction of CAR T-cells are not only biologically complex, but they can significantly influence toxicity, remission durability, and long-term outcomes. The ExPeCT anti-CD19 (obe-cel) assay was developed to address this gap by turning post-infusion uncertainty into clear, quantitative insight. 

Unlike traditional observational monitoring, this test captures the unique biology of this fast off-rate CD19 CAR construct. These next-generation CAR designs disengage rapidly from antigen targets and prioritize controlled activation and sustained persistence.

The ExPeCT antiCD19 (obe-cel) assay meets this need through a highly specific approach that targets regions of the CAR construct to detect them across clinical samples. This allows clinicians to visualize expansion kinetics and assess persistence patterns that may signal early relapse risk or durable remission.  

For Heme/Onc clinicians, the results generated may be a powerful tool for proactive care: earlier insight into therapeutic effectiveness, improved ability to anticipate toxicities, and a clearer understanding of whether CAR T-cells are performing as intended. For laboratory scientists, the assay offers an analytically validated, and reproducible framework. Together, the capabilities of the ExPeCT brand of CAR T-cell assays turn CAR T monitoring from a retrospective exercise into a forward looking analysis that informs patient management at every critical stage of therapy. This non-invasive blood test delivers results in approximately 24 hours after specimen receipt. 

Leading Edge Monitoring of CAR T-cell Therapy

Learn More